A soluble form of the glycolipid‐anchored receptor for urokinase‐type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria
- 1 September 1992
- journal article
- research article
- Published by Wiley in European Journal of Biochemistry
- Vol. 208 (2) , 397-404
- https://doi.org/10.1111/j.1432-1033.1992.tb17200.x
Abstract
The cellular urokinase-type plasminogen-activator (uPA) receptor (uPAR) is a glycolipid-anchored membrane protein thought to be involved in pericellular proteolysis during cell migration and tumor invasion. In the present study, we have identified and characterized two soluble forms of uPAR which have retained their ligand-binding capability. One variant was generated in vitro by treatment of intact normal cells with either a phosphatidylinositol-specific phospholipase C (PLC) or endoproteinase Asp-N. The other soluble uPAR variant was secreted in vivo from peripheral blood leukocytes affected by the stem-cell disorder paroxysmal nocturnal hemoglobinuria (PNH), and was found in the plasma from these PNH patients as well as in the conditioned medium from cultured PNH leukocytes. Under normal conditions, we find no evidence for any shedding or secretion of a soluble uPA-binding counterpart to human uPAR in plasma. Unlike normal leukocytes, the PNH-affected cells do not express uPAR on the cell surface, although they do contain apparently normal levels of uPAR-specific mRNA. The secreted uPAR derived from PNH cells has a mobility in SDS/PAGE that is slightly higher than that of uPAR solubilized by PtdIns-specific PLC or detergent, but resembles that of a truncated, recombinant uPAR variant, which has its C-terminus close to the proposed glycolipid-attachment site, suggesting that the secreted protein has been proteolytically processed for glycolipid attachment. The presence in plasma from PNH patients of such a secreted, hydrophilic form of uPAR lends support to the hypothesis that the lesion underlying the PNH disorder resides either in glycolipid biosynthesis or in the function of an as-yet-unidentified transamidating enzyme assumed to cleave and assemble the truncated uPAR with the preformed glycolipid moiety.Keywords
This publication has 47 references indexed in Scilit:
- Differential Expression of Urokinase-Type Plasminogen Activator and Its Type-1 Inhibitor During Healing of Mouse Skin WoundsJournal of Investigative Dermatology, 1991
- Membrane proteins with soluble counterparts: role of proteolysis in the release of transmembrane proteinsBiochemistry, 1991
- Antibodies to Proteus in Rheumatoid ArthritisRheumatology, 1991
- Protein Structure and Membrane Anchorage of the Cellular Receptor for Urokinase-Type Plasminogen ActivatorSeminars in Thrombosis and Hemostasis, 1991
- Estimation of PI‐bound proteins on blood cells from PNH patients by quantitative flow cytometryBritish Journal of Haematology, 1990
- Deciphering Alzheimer's Disease: The Amyloid Precursor Protein Yields New CluesScience, 1990
- Urokinase receptors in human monocytesBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1990
- Synthesis of aberrant decay-accelerating factor proteins by affected paroxysmal nocturnal hemoglobinuria leukocytes.Journal of Clinical Investigation, 1990
- In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase.The Journal of cell biology, 1988
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970